FDA approves lofexor as liquid biologic therapy for advanced breast cancer patients
A one-time dose-escalation strategy has been implemented with the proposed 5-year product life.
The company is also developing Andrapan, a combination lofexor inhibitor/anti-HIV combination therapy product, with potential for one-time-treatment, extended treatment, and two-year dosing, and intends to begin clinical assessments in early 2022.
Pfizer, Moderna, Mylan NV, and Valneva Pharmaceuticals Plc, Inc.